JU09 Rec'd PCT/PTO 24 OCT 2005

FORM PTO-1390 (Modified) REV. 2-2005) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE ATTORNEY'S DOCKET NUMBER 280125US0PCT TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
10/554399 DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/SE04/00590 15 April 2004 24 April 2003 earliest TITLE OF INVENTION PODOPHYLLOTOXIN DERIVATIVES AS IGF-1R INHIBITORS APPLICANT(S) FOR DO/EO/US Magnus AXELSON et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: Ø This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. \boxtimes This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), 3. (9) and (24) indicated below. The US has been elected (Article 31). \boxtimes 4. 5. \boxtimes A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) а. 🛚 is attached hereto (required only if not communicated by the International Bureau). b. 🔯 has been communicated by the International Bureau. c. 🗆 is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🗆 is attached hereto. b. □ has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) а. П are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. c. 🗆 have not been made; however, the time limit for making such amendments has NOT expired. \boxtimes have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). \boxtimes A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. A FIRST preliminary amendment. 16. A SECOND or SUBSEQUENT preliminary amendment. 17. A substitute specification. 18. A power of attorney and/or change of address letter. 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 20. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 21. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 22. Express Mail Label No. \bowtie 23. Other items or information: **Application Data Sheet** Notice of Priority (2) Request for Consideration

JCO9 Rec'd PCT/PTO 9 A OCT 2005.

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION OF BUT STATES OF OF OF OF			INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER.	
			PCT/SE04/00590			280125US0PCT	
The following fees are submitted:						CALCULATIONS	PTO USE
24. 🗵 Basic national fee						\$ \$300.00	
25. ⊠ Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)						\$ \$200.00	
26. Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority						\$ \$400.00 \$ \$900.00	
Additional fe sequence lis \$250 for each	e for specification ting or computer p h additional 50 she						
Total Sheets	Extra Sheets				RATE		
- 100 =	0 /50 =	0			× \$250.00	\$ \$0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).						\$ \$130.00	
CLAIMS	CLAIMS NUMBER FILED NUMBER EXTRA				RATE		
Total claims	51	51 - 20 =		x	\$50.00	\$ \$1,550.00	
Independent clair	ndent claims 3 - 3 =		0	х	\$200.00	\$ \$0.00	
MULTIPLE DEPENDENT CLAIMS (if applicable) □ + \$360.00						\$ \$360.00	
TOTAL OF ABOVE CALCULATIONS =						\$ \$2,940.00	
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.						\$ \$0.00	
SUBTOTAL =						\$ \$2,940.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$ \$0.00	
TOTAL NATIONAL FEE =						\$ \$2,940.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$ \$0.00	
TOTAL FEES ENCLOSED =						\$ \$2,940.00	
						Amount to be	\$
						Amount to be	s
a. A check in the amount of \$ to cover the above fees is enclosed.							
b. Please charge my Deposit Account No. in the amount of to cover the above fees. A duplicate copy of this sheet is enclosed.							
c. The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 15-0030 . A duplicate copy of this sheet is enclosed.							
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.							
SEND ALL CORRESPONDENCE TO:						Suurch Son	hos
Customer Number SIGNATURE						<i>p</i>	
22850 Norman F						. Oblon	
Surinder Sachar Registration No. 34,423 REGISTRAT							
						TON NUMBER	

JC09 Rec'd PCT/PTO 2'4 OCT 2005

DOCKET NO.: 280125US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Magnus AXELSON, et al.

SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HEREWITH

INTERNATIONAL APPLICATION NO.: PCT/SE04/00590

INTERNATIONAL FILING DATE: April 15, 2004

FOR: PODOPHYLLOTOXIN DERIVATIVES AS IGF-1R INHIBITORS

REQUEST FOR PRIORITY UNDER 35 U.S.C. 119 AND THE INTERNATIONAL CONVENTION

Commissioner for Patents Alexandria, Virginia 22313

Sir:

In the matter of the above-identified application for patent, notice is hereby given that the applicant claims as priority:

COUNTRY

APPLICATION NO

DAY/MONTH/YEAR

Sweden

0301202-8

24 April 2003

Certified copies of the corresponding Convention application(s) were submitted to the International Bureau in PCT Application No. PCT/SE04/00590.

Respectfully submitted, OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Customer Number 22850

(703) 413-3000 Fax No. (703) 413-2220 (OSMMN 08/03) Norman F. Oblon Attorney of Record Registration No. 24,618

Surinder Sachar

Registration No. 34,423

JC09 Rec'd PCT/PTO 24 OCT 2005.

DOCKET NO.: 280125US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Magnus AXELSON, et al.

SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HEREWITH

INTERNATIONAL APPLICATION NO.: PCT/SE04/00590

INTERNATIONAL FILING DATE: April 15, 2004

FOR: PODOPHYLLOTOXIN DERIVATIVES AS IGF-1R INHIBITORS

REQUEST FOR PRIORITY UNDER 35 U.S.C. 119(e) AND THE INTERNATIONAL CONVENTION

Commissioner for Patents Alexandria, Virginia 22313

Sir:

In the matter of the above-identified application for patent, notice is hereby given that the applicant claims as priority:

COUNTRY USA **APPLICATION NO**

DAY/MONTH/YEAR

60/468,054 06 May 2003

Certified copies of the corresponding Convention application(s) were submitted to the International Bureau in PCT Application No. PCT/SE04/00590.

Respectfully submitted, OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon Attorney of Record Registration No. 24,618 Surinder Sachar

Registration No. 34,423

Customer Number 22850

(703) 413-3000 Fax No. (703) 413-2220 (OSMMN 08/03)

JC09 Rec'd PCT/PTO 24 OCT 2005,

DOCKET NO.: 280125US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Magnus AXELSON, et al.

SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HEREWITH

INTERNATIONAL APPLICATION NO.: PCT/SE04/00590

INTERNATIONAL FILING DATE: April 15, 2004

FOR: PODOPHYLLOTOXIN DERIVATIVES AS IGF-1R INHIBITORS

REQUEST FOR CONSIDERATION OF DOCUMENTS CITED IN INTERNATIONAL SEARCH REPORT

Commissioner for Patents Alexandria, Virginia 22313

Sir:

In the matter of the above-identified application for patent, notice is hereby given that applicant(s) request that the Examiner consider the documents cited in the International Search Report according to MPEP §609 and so indicate by a statement in the first Office Action that the information has been considered. When the Form PCT/DO/EO/903 indicates both the search report and copies of the documents are present in the national stage file, there is no requirement for the applicant(s) to submit them (1156 O.G. 91 November 23, 1993).

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon Attorney of Record

Registration No. 24,618

Surinder Sachar

Registration No. 34,423

Customer Number 22850

(703) 413-3000 Fax No. (703) 413-2220 (OSMMN 08/03)